Inverseon's INV102 Asthma Product Discussed at the European Respiratory Society
9/22/2009 12:15:48 PM
San Francisco, CA, Sept 22, 2009 – A symposium was held last week at the European Respiratory Society’s annual meeting in Vienna, Austria entitled, “Beta-blockers may now be beneficial in asthma and COPD."
“It is remarkable how far Inverseon’s asthma program has advanced in the past couple of years. We now have data from two clinical trials and evidence is accumulating that INV102 is showing pre-clinical activity with respect to each of the major hallmarks of asthma: Airway hyperresponsiveness, inflammation, and mucous hypersecretion,” stated Amie E. Franklin, PhD of Inverseon.
“The symposium at an international respiratory conference demonstrated that the approach of using certain beta-blockers in asthmatics is gaining increasing scientific and clinical recognition,” stated Richard A. Bond, scientific founder of Inverseon and Prof. of Pharmacology at the University of Houston.
“The presentations very much support the clinical development of our proprietary controlled-release oral formulation, INV102CR. We believe that INV102CR may provide an important steroid sparing treatment option in an oral dosage form,” said William J. Garner, MD, Chairman of Inverseon.
About Inverseon, Inc.
Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.